Aldeyra Therapeutics (ALDX) Interest Expenses (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Interest Expenses of $468678.0 for Q1 2026, down 26.55% on a QoQ basis from $638060.0 in Q4 2025, and down 94.25% year-over-year from $8.2 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Interest Expenses (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Interest Expenses history runs 14 years deep, the most recent figure standing at $468678.0 for Q1 2026.
- Quarterly Interest Expenses fell 94.25% year-over-year to $468678.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 75.36% YoY) and the FY2025 annual result came in at $6.6 million, up 35.24% from the prior year.
- Interest Expenses was $468678.0 for Q1 2026 at Aldeyra Therapeutics, down from $638060.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $26.4 million in Q1 2023 and bottomed at $424625.0 in Q4 2024.
- A 5-year average of $5.2 million and a median of $1.6 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses plunged 98.11% — and 2025, when it surged 1535.74%.
- Aldeyra Therapeutics' Interest Expenses stood at $712265.0 in 2022, then gained by 13.59% to $809081.0 in 2023, then sank by 47.52% to $424625.0 in 2024, then jumped by 50.26% to $638060.0 in 2025, then dropped by 26.55% to $468678.0 in 2026.
- Business Quant data shows ALDX's Interest Expenses at $468678.0 in Q1 2026, $638060.0 in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 1.17 Bn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | 468,678.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 468,678.00 |
| Mar 31, 2026 | 468,678.00 |
| Dec 31, 2025 | 638,060.00 |
| Dec 31, 2025 | 638,060.00 |
| Sep 30, 2025 | 6.81 Mn |
| Sep 30, 2025 | 6.81 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Dec 31, 2024 | 424,625.00 |
| Dec 31, 2024 | 424,625.00 |
| Sep 30, 2024 | 7.39 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 477,601.00 |
| Jun 30, 2024 | 477,601.00 |
| Mar 31, 2024 | 498,526.00 |
| Mar 31, 2024 | 498,526.00 |
| Dec 31, 2023 | 809,081.00 |
| Dec 31, 2023 | 809,081.00 |